PubRank

Socrates E Papapoulos

Author PubWeight™ 52.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004 3.88
2 Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005 3.61
3 Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology 2002 2.49
4 Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 2010 2.21
5 Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab 2005 2.05
6 SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 2005 1.88
7 Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 2007 1.76
8 Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. Bone 2010 1.68
9 Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res 2007 1.63
10 BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol 2007 1.58
11 Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging 2004 1.42
12 Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res 2009 1.41
13 Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 2005 1.37
14 Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res 2005 1.33
15 Prolonged bisphosphonate release after treatment in children. N Engl J Med 2007 1.32
16 Bone material strength as measured by microindentation in vivo is decreased in patients with fragility fractures independently of bone mineral density. J Clin Endocrinol Metab 2015 1.22
17 Peroxisome proliferator-activated receptor gamma (PPARgamma ) as a molecular target for the soy phytoestrogen genistein. J Biol Chem 2002 1.21
18 Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption. J Med Chem 2005 1.12
19 Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res 2011 1.11
20 Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice. J Bone Miner Res 2002 1.06
21 Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers. J Bone Miner Res 2013 1.06
22 Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practice. J Clin Densitom 2011 1.00
23 Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover. Bone 2012 0.93
24 Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. J Bone Miner Res 2005 0.92
25 Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. Eur J Nucl Med Mol Imaging 2002 0.91
26 Inhibition of bone resorption and growth of breast cancer in the bone microenvironment. Bone 2008 0.90
27 Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass. Bone 2012 0.86
28 Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res 2002 0.86
29 Short term whole body retention in relation to rate of bone resorption and cartilage degradation after intravenous bisphosphonate (pamidronate) in rheumatoid arthritis. J Rheumatol 2004 0.86
30 SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development. Dev Dyn 2007 0.84
31 Normal growth and muscle dysfunction in X-linked hypophosphatemic rickets associated with a novel mutation in the PHEX gene. J Clin Endocrinol Metab 2008 0.83
32 Increased circulating levels of FGF23: an adaptive response in primary hyperparathyroidism? Eur J Endocrinol 2011 0.82
33 Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis. Drugs 2015 0.81
34 Medical treatment of hypercalcaemia. Hormones (Athens) 2009 0.81
35 Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone. J Bone Miner Res 2003 0.81
36 Low-energy fractures of the humeral shaft and bisphosphonate use. J Bone Miner Res 2012 0.80
37 Glucocorticoids are not always deleterious for bone. J Bone Miner Res 2010 0.80
38 Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy. J Bone Miner Res 2002 0.79
39 No effect of rosuvastatin in the zoledronate-induced acute-phase response. Calcif Tissue Int 2011 0.79
40 Absorption of the oral bisphosphonate alendronate in osteoporotic patients with Crohn's disease. Osteoporos Int 2005 0.78
41 Paget's disease of bone in The Netherlands: a population-based radiological and biochemical survey--the Rotterdam Study. J Bone Miner Res 2004 0.78
42 Severe hypophosphatemic osteomalacia in hormone-refractory prostate cancer metastatic to the skeleton: natural history and pitfalls in management. Bone 2004 0.77
43 Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy. Bone 2003 0.76
44 Bone diseases: bisphosphonates in osteoporosis--beyond 5 years. Nat Rev Rheumatol 2013 0.76
45 In Memoriam: Olav Bijvoet 1928–2014. Bone 2014 0.75